Mykofenolsyra Accord 360 mg Enterotablett Sverige - svenska - Läkemedelsverket (Medical Products Agency)

mykofenolsyra accord 360 mg enterotablett

accord healthcare b.v. - mykofenolatnatrium - enterotablett - 360 mg - mykofenolatnatrium 384,7 mg aktiv substans; natriumlaurilsulfat hjälpämne; propylenglykol hjälpämne - mykofenolsyra

Myfortic 360 mg Enterotablett Sverige - svenska - Läkemedelsverket (Medical Products Agency)

myfortic 360 mg enterotablett

ebb medical ab - mykofenolatnatrium - enterotablett - 360 mg - mykofenolatnatrium 384,8 mg aktiv substans; laktos (vattenfri) hjälpämne - mykofenolsyra

Myfortic 360 mg Enterotablett Sverige - svenska - Läkemedelsverket (Medical Products Agency)

myfortic 360 mg enterotablett

abacus medicine a/s - mykofenolatnatrium - enterotablett - 360 mg - laktos (vattenfri) hjälpämne; mykofenolatnatrium 384,8 mg aktiv substans

Mykofenolsyra Medartuum 180 mg Enterotablett Sverige - svenska - Läkemedelsverket (Medical Products Agency)

mykofenolsyra medartuum 180 mg enterotablett

medartuum ab - mykofenolatnatrium - enterotablett - 180 mg - laktos (vattenfri) hjälpämne; mykofenolatnatrium 192,4 mg aktiv substans

Myfortic 180 mg Enterotablett Sverige - svenska - Läkemedelsverket (Medical Products Agency)

myfortic 180 mg enterotablett

2care4 aps - mykofenolatnatrium - enterotablett - 180 mg - laktos (vattenfri) hjälpämne; mykofenolatnatrium 192,4 mg aktiv substans

Myfortic 360 mg Enterotablett Sverige - svenska - Läkemedelsverket (Medical Products Agency)

myfortic 360 mg enterotablett

2care4 aps - mykofenolatnatrium - enterotablett - 360 mg - laktos (vattenfri) hjälpämne; mykofenolatnatrium 384,8 mg aktiv substans

Mykofenolsyra Medartuum 360 mg Enterotablett Sverige - svenska - Läkemedelsverket (Medical Products Agency)

mykofenolsyra medartuum 360 mg enterotablett

medartuum ab - mykofenolatnatrium - enterotablett - 360 mg - laktos (vattenfri) hjälpämne; mykofenolatnatrium 384,8 mg aktiv substans

Jayempi Europeiska unionen - svenska - EMA (European Medicines Agency)

jayempi

nova laboratories ireland limited - azathioprine - graftförkastning - immunsuppressiva - jayempi is indicated in combination with other immunosuppressive agents for the prophylaxis of transplant rejection in patients receiving allogenic kidney, liver, heart, lung or pancreas transplants. azathioprine is indicated in immunosuppressive regimens as an adjunct to immunosuppressive agents that form the mainstay of treatment (basis immunosuppression). jayempi is used as an immunosuppressant antimetabolite either alone or, more commonly, in combination with other agents (usually corticosteroids) and/ or procedures which influence the immune response. jayempi is indicated in patients who are intolerant to glucocorticosteroids or if the therapeutic response is inadequate despite treatment with high doses of glucocorticosteroids, in the following diseases:severe active rheumatoid arthritis (chronic polyarthritis) that cannot be kept under control by less toxic agents (disease-modifying anti-rheumatic -medicinal products – dmards)auto-immune hepatitis systemic lupus erythematosusdermatomyositispolyarteritis nodosapemphigus vulgaris and bullous pemphigoidbehçet’s diseaserefractory auto-immune haemolytic anaemia, caused by warm igg antibodieschronic refractory idiopathic thrombocytopenic purpurajayempi is used for the treatment of moderately severe to severe forms of chronic inflammatory bowel disease (ibd) (crohn’s disease or ulcerative colitis) in patients in whom glucocorticosteroid therapy is necessary, but where glucocorticosteroids are not tolerated, or in whom the disease is untreatable with other common means of first choice. it is also indicated in adult patients in relapsing multiple sclerosis, if an immunomodulatory therapy is indicated but beta interferon therapy is not possible, or a stable course has been achieved with previous treatment with azathioprine. 3jayempi is indicated for the treatment of generalised myasthenia gravis. depending on the severity of the disease, jayempi should be given in combination with glucocorticosteroids because of slow onset of action at the beginning of treatment and the glucocorticosteroid dose should be gradually reduced after several months of treatment.

Fevarin 100 mg Filmdragerad tablett Sverige - svenska - Läkemedelsverket (Medical Products Agency)

fevarin 100 mg filmdragerad tablett

viatris ab - fluvoxaminmaleat - filmdragerad tablett - 100 mg - mannitol hjälpämne; fluvoxaminmaleat 100 mg aktiv substans - fluvoxamin

Fevarin 100 mg Filmdragerad tablett Sverige - svenska - Läkemedelsverket (Medical Products Agency)

fevarin 100 mg filmdragerad tablett

cross pharma ab - fluvoxaminmaleat - filmdragerad tablett - 100 mg - mannitol hjälpämne; fluvoxaminmaleat 100 mg aktiv substans - fluvoxamin